Statin drugs for the treatment of erectile dysfunction:An umbrella review

LI Ze; ZHANG Pei-hai; LIU Mei-jun; ZHANG Tao

doi:10.13263/j.cnki.nja.2025.07.010

Abstract：Objective:The aim of this study is to re-evaluate the systematic reviews and meta-analyses on statins for the treat-ment of erectile dysfunction(ED)and construct an umbrella review,thereby providing robust evidence-based for the clinical applica-tion of statins in ED treatment.Methods:A comprehensive computerized search was conducted across CNKI,Wanfang Database,VIP,WOS,Embase,PubMed,and Cochrane Library databases from their inception to September 12,2024,for all systematic reviews and meta-analyses addressing statin interventions in ED.The methodological quality,reporting quality,and evidence quality of the in-cluded studies were assessed and summarized using PRISMA 2020,AMSTAR 2,and GRADE systems.Results:Four systematic re-views and meta-analyses were included.According to the AMSTAR 2 evaluation,one paper was rated as low quality,while the remai-ning three were classified as very low quality.PRISMA 2020 evaluation results indicated that the average score of the four included studies was 29,with all being of medium quality but exhibiting partial deficiencies.The proportion of fully consistent items across the four studies ranged from 52.38％to 80.95％.GRADE system tool evaluation revealed 11 outcome indicators,of which only one was rated as intermediate evidence.The remainders were categorized as low or very low evidence,with no high-quality evidence identified.Conclusion:Statins demonstrate efficacy in treating ED.However,the current quality of relevant systematic reviews is suboptimal,with notable deficiencies in methodological,reporting,and evidential quality.Further high-quality studies are warranted to provide more reliable evidence-based medical guidance for clinical practice.